Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCapital Bluecross Value Formulary Coverage & PA | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCapital BluecrossPolicy N/A

    Value Formulary (2026) — Prescription Drug List and Utilization Management

    Customize your policy alerts

    Sign up for all Capital Bluecross policy alerts

    Know when Capital Bluecross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the Capital Blue Cross 2026 Value Formulary for prescription drugs, including formulary tiers, specialty drug handling, utilization management (prior authorization, step therapy, quantity limits), and processes for exceptions and reconsideration; applies to members and providers under Capital Blue Cross plans governed by this formulary.

    Policy Summary
    PayerCapital Bluecross
    PolicyValue Formulary (2026) — Prescription Drug List and Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionReference the formulary columns (Prior Authorization; Step Therapy; Quantity Limits; Limited Distribution) to determine required utilization management actions and dispensing instructions.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026Formulary year
    AccredoDesignated specialty pharmacy
    Prime TherapeuticsBenefit manager
    30-daySpecialty supply limit
    multipleVaccine listings

    Formulary Coverage & Exclusions

    Formulary Coverage and Utilization Management

    Covered when ALL of the following plan- and formulary-level conditions are met:

    Formulary Coverage Basics: Drug must be FDA‑approved as evidenced by an NDA, ANDA, or BLA on file unless superseded by legal requirements or group‑specific benefits; non‑FDA‑approved drugs are not covered. Providers may request a nonformulary exception if they believe a new drug is medically necessary.

    Source: Coverage considerations (FDA approval) and Nonformulary exception process.

    Benefit Verification: Member coverage is subject to the terms of the member's Certificate of Coverage (benefit booklet) and plan‑specific pharmacy benefit design; listing in the formulary does not guarantee coverage or payment.

    Check member's Certificate of Coverage and plan materials before prescribing.

    Supply Limits: Most prescription drugs: up to a 30‑day supply; maintenance drugs may be covered up to a 90‑day supply; specialty drugs are limited to a 30‑day supply.
    Policy Summary
    PayerCapital Bluecross
    PolicyValue Formulary (2026) — Prescription Drug List and Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionReference the formulary columns (Prior Authorization; Step Therapy; Quantity Limits; Limited Distribution) to determine required utilization management actions and dispensing instructions.
    SourceLink
    On This Page
    Formulary Coverage & ExclusionsDrug Listings and Code TablesPrior Authorization, Step Therapy, Quantity Limits & ReconsiderationStep Therapy Rules & IndicatorsQuantity Limits & Dispensing ConstraintsSite of Care and Medical Benefit NotesTerminology and AbbreviationsPolicy Background
    30‑day specialty; up to 90‑day maintenance

    See Additional coverage considerations.

    Utilization Management: Prior authorization, step therapy, and quantity level limits may apply; when commonly required an indicator (dot) is shown in the formulary columns, but absence of an indicator in this document does not guarantee the requirement is not applied at the plan level.

    Refer to prescription drug plan materials for plan‑specific UM requirements.

    Quantity Level Limits (QLL): Certain drugs have quantity level limits (per prescription, per time period, age or gender restrictions); if prescribed quantity exceeds the QLL the member is responsible for cost beyond allowed coverage unless an authorization is obtained.Varies by drug

    See Utilization management (Quantity Level Limits).

    Specialty Distribution and Limited Distribution: Specialty drugs are distributed through the plan's specialty pharmacy (Accredo). Some specialty products are limited distribution and must be dispensed by specified pharmacies; members/providers should contact Accredo for enrollment and dispensing information.

    Contact Accredo or member services for limited distribution instructions.

    Exclusions are plan- and contract-specific. Examples noted in the formulary materials include exclusions for drugs used for cosmetic purposes, appetite suppressants, erectile dysfunction drugs, non–self‑administered injectable drugs, experimental or investigational (including off‑label) use, certain vitamins (non‑prenatal), and products with OTC equivalents. Members should consult their Certificate of Coverage for the final determination of whether a given product is excluded under their plan.

    The provided formulary segments in this excerpt do not include explicit exclusion statements; they are product listings used for billing and coverage reference. Absence of an exclusion statement in these chunks does not guarantee coverage — coverage remains subject to the member's plan benefits and any utilization management rules indicated elsewhere in the formulary.

    This catalog-style excerpt lists vaccine and antineoplastic products and does not state explicit coverage exclusions for the items shown. Use the formulary columns and the member’s Certificate of Coverage to determine applicable utilization management or coverage limitations for listed products.

    The antineoplastic product listing in this chunk enumerates therapy packs and formulations but does not include specific exclusion language. Coverage determinations for oncology agents are governed by plan benefits and any utilization management requirements indicated in the formulary.

    This segment contains endocrine and corticosteroid product listings (including fludrocortisone and hydrocortisone) without explicit exclusion statements. Providers should reference plan documents and formulary utilization indicators for coverage and dispensing instructions.

    Listings for testosterone transdermal gels and related formulations are presented here without explicit exclusion language. Coverage of androgen preparations is subject to plan benefit rules and any utilization management indicators shown in the formulary.

    Diabetes therapy agents such as sitagliptin (JANUVIA) and metformin combinations are listed in this excerpt. No explicit coverage exclusions are stated in this portion; coverage and any quantity or prior authorization limits are determined by the member’s plan and the formulary columns.

    Insulin product presentations (e.g., LYUMJEV pen formats) are enumerated without exclusion statements. Specialty distribution, supply limits, and any utilization management requirements should be confirmed via the formulary columns and the member’s Certificate of Coverage.

    This section lists specialty metabolic agents (e.g., sapropterin/Kuvan and sodium phenylbutyrate/Buphenyl) as product entries. The excerpt does not include explicit exclusions; coverage and any restricted distribution or prior authorization requirements are determined by plan rules.

    Repeated listings of digoxin oral solution are provided here as product entries without an explicit coverage stance in the excerpt. Determinations of coverage, supply limits, and any utilization management are controlled by the member’s benefit plan and the formulary indicators.

    The product listings in these chunks do not include any statements designating items as "not medically necessary." Where such determinations apply, they would be reflected in the member’s benefit documentation or separate medical policy language.

    There are no explicit “not medically necessary” determinations present in these vaccine and oncology listing excerpts. Clinical coverage determinations are made according to product labeling, utilization management rules, and the member’s Certificate of Coverage.

    No "not medically necessary" statements appear in this antineoplastic agent listing. Coverage for oncology drugs depends on plan benefits and any applicable prior authorization or other utilization management requirements.

    The testosterone and related endocrine product entries in this excerpt do not include determinations that they are "not medically necessary." Coverage is governed by plan rules and any indicated utilization management criteria.

    This diabetes agent listing does not contain "not medically necessary" language. Coverage and any applicable limits or prior authorization requirements should be verified through the formulary columns and the member’s benefit documents.

    Insulin product listings in this excerpt do not include explicit "not medically necessary" statements. Any determination of medical necessity will follow plan criteria and utilization management policies.

    The anti‑infective product listings in these chunks do not state any "not medically necessary" decisions. Clinical appropriateness and coverage are determined by product labeling, formulary placement, and the member’s Certificate of Coverage.

    Formulary listing segments that are purely product inventories generally do not include explicit "not medically necessary" language. Any such determinations would be contained in separate policy statements or benefit documentation.

    Drug Listings and Code Tables

    Anti-infective drug entries (partial)NDC | textual
    flucytosine cap 250 mg; 500 mgflucytosine (Ancobon)
    griseofulvin microsize susp 125 mg/mlgriseofulvin microsize suspension 125 mg/mL
    griseofulvin microsize tab 500 mggriseofulvin microsize tablet 500 mg
    Anti-infective drug entries (partial)NDC | textual
    ketoconazole tab 200 mgketoconazole 200 mg tablet
    nystatin tab 500000 unitnystatin 500,000 unit tablet
    terbinafine hcl tab 250 mgterbinafine 250 mg tablet
    Antifungals and antiretroviralsNDC | textual
    voriconazole tab 50 mg; 200 mgvoriconazole (Vfend) 50 mg and 200 mg tablets
    abacavir sulfate tab 300 mgabacavir sulfate 300 mg tablet (Ziagen)
    emtricitabine-tenofovir disoproxil fumarate tab 200-300 mgTruvada (emtricitabine + TDF)
    AntiviralsNDC | textual
    acyclovir cap 200 mgacyclovir 200 mg capsule
    acyclovir susp 200 mg/mlacyclovir suspension 200 mg/mL (Zovirax)
    EPCLUSA sofosbuvir-velpatasvir tab 200-50 mg, 400-100 mgEpclusa (sofosbuvir-velpatasvir)
    HIV/HCV related agentsNDC | textual
    APRETUDE cabotegravir im extended release susp 600Apretude 600 mg IM suspension
    atazanavir sulfate cap 150 mg; 200 mg; 300 mgatazanavir (Reyataz) capsules
    HARVONI ledipasvir-sofosbuvir tab 45-200 mg; 90-400 mgHarvoni (ledipasvir-sofosbuvir)
    COMPLERA emtricitabine-rilpivirine-tenofovir df tabComplera fixed-dose combination
    HIV agentsNDC | textual
    darunavir tab 600 mg; 800 mgdarunavir (Prezista)
    ISENTRESS raltegravir packet / tabIsentress formulations (chewable 25 mg, 100 mg; packet 100 mg; tab 400 mg)
    DELSTRIGO doravirine-lamivudine-tenofovir df tabDelstrigo fixed-dose combination
    Oral antivirals and formulationsNDC | textual
    LAGEVRIO molnupiravir cap 200 mgMolnupiravir (Lagevrio) 200 mg capsules
    lamivudine oral soln 10 mg/ml (Epivir)lamivudine oral solution 10 mg/mL
    lamivudine tab 100 mg (Epivir HBV)lamivudine 100 mg tablet for HBV
    Additional antiviral/HIV entriesNDC | textual
    LEDIPASVIRISOFOSBUVIR ledipasvir-sofosbuvir tab 90-400 mgLedipasvir-sofosbuvir
    lopinavir-ritonavir tab 100-25 mg; 200-50 mg (Kaletra)lopinavir/ritonavir formulations
    maraviroc tab 150 mg; 300 mg (Selzentry)maraviroc tablets
    TIVICAY dolutegravir sodium tab 50 mgDolutegravir (Tivicay) 50 mg tablet
    ODEFSEY emtricitabine-rilpivirine-tenofovir af tab 200-25-25 mgOdefsey fixed-dose combination
    Vaccine product listingmixed
    COMIRNATY 2025-26covid-19 mRNA vaccine tris - Pfizer, various age formulations (30 mcg/0.3ml; 10 mcg/0.3ml for 5-11y)
    GARDASIL 9human papillomavirus (HPV) 9-valent recombinant vaccine
    HAVRIX / VAQTA / RECOMBIVAX HB / ENGERIX-B / HEPLISAV-BHepatitis A and B vaccine formulations listed with concentrations and prefilled syringes
    FLUAD / FLUARIX2025-2026 influenza vaccine formulations (adjuvanted and split virus preparations)
    JYNNEOSsmallpox & monkeypox vaccine, live non-replicating, 0.5 ml
    M-M-R II / PRIORIXmeasles-mumps-rubella virus vaccines
    MENVEO / TRUMENBA / PENBRAYAmeningococcal vaccines (A,C,Y,W-135 and B formulations)
    VARIVAXvaricella virus vaccine live for injection
    MRESVIARSV mRNA pre-f vaccine (50 mcg/0.5 ml)
    NOVAVAX / MODERNA / SPIKEVAXadditional COVID-19 vaccine products (Novavax subunit, Moderna formulations)
    1–10 of 13
    1/2
    Antineoplastic / oncology product listingmixed
    IBRANCEpalbociclib tablets (75 mg, 100 mg, 125 mg)
    COTELLICcobimetinib fumarate tablets 20 mg
    ALECENSAalectinib HCl capsules 150 mg
    LENVIMA (multiple daily dose packs)lenvatinib capsule therapy packs (4 mg, 8 mg, 10 mg, 12 mg, 18 mg, 20 mg, 24 mg daily dose packs)
    POMALYSTpomalidomide capsules (2.3 mg, 3 mg, 4 mg)
    METHOTREXATE SODIUMinjectable methotrexate sodium 50 mg/2 mL and oral formulations
    IMATINIB (Gleevec)imatinib mesylate tablets (100 mg, 400 mg)
    HYDROXYUREAhydroxyurea capsules 500 mg
    SOLTAMOXtamoxifen citrate oral solution 10 mg/mL
    ERIVEDGE / IBRANCE / POMALYST / etc.additional antineoplastic agents listed by name and formulation
    Lenvima formulations listedmixed
    lenvatinib 18 mgLENVIMA 18 MG DAILY DOSE lenvatinib cap therapy pack (10 mg & 2 x 4 mg)
    lenvatinib 20 mgLENVIMA 20 MG DAILY DOSE lenvatinib cap therapy pack (2 x 10 mg)
    lenvatinib 24 mgLENVIMA 24 MG DAILY DOSE lenvatinib cap therapy pack (2 x 10 mg & 4 mg)
    Talzenna formulationsmixed
    talazoparibTALZENNA talazoparib tosylate cap 0.1 mg; 0.25 mg; 0.35 mg; 0.5 mg; 0.75 mg
    Additional antineoplastic oral agentsmixed
    tamoxifentamoxifen citrate tab 10 mg; 20 mg (SOLTAMOX mentioned)
    nilotinibTASIGNA nilotinib hcl cap 50 mg; 150 mg; 200 mg
    crizotinibXALKORI crizotinib cap 200 mg; 250 mg
    Oral chemotherapy agentsmixed
    temozolomidetemozolomide cap 5 mg
    toremifenetoremifene citrate tab 60 mg (Fareston)
    Cytotoxic and targeted agentsmixed
    methotrexateTREXALL methotrexate sodium tab 5 mg; 7.5 mg; 10 mg
    idelalisibZYDELIG idelalisib tab 100 mg; 150 mg
    Endocrine/metabolic and corticosteroid agentsmixed
    prednisone/prednisolone/methylprednisolone/dexamethasoneMultiple corticosteroid oral and solution formulations (prednisone, prednisolone, methylprednisolone, dexamethasone) in various strengths and pack types
    testosterone formulationsMultiple testosterone formulations: gels (Androgel), injections (cypionate, enanthate), TD gels in various strengths
    fludrocortisone/hydrocortisonefludrocortisone acetate tab 0.1 mg; hydrocortisone tab 5 mg; 10 mg; 20 mg
    Miscellaneous listed agentsmixed
    tamoxifen oral solutionSOLTAMOX tamoxifen citrate oral soln 10 mg/ml
    tretinointretinoin cap 10 mg
    treatment combinationsVarious supportive/simultaneous listings (e.g., corticosteroids listed among antineoplastic agents)
    Listed drug products (no billing codes in excerpt)mixed
    No codes listed
    Listed oral diabetes agentsmixed
    JANUVIA 25 mg, 50 mg, 100 mgsitagliptin formulations listed (base equivalent)
    metformin HCl tab 5-500 mg, 5-1000 mg, 12.5-500 mg, 12.5-1000 mgmetformin combination/strength listings
    Listed SGLT2 and GLP-1 agentsmixed
    JARDIANCE 10 mg, 25 mgempagliflozin tablets
    SYNJARDY XR (empagliflozin-metformin ER) 5-1000 mg; 10-1000 mg; 12.5-1000 mgcombination empagliflozin/metformin extended release
    liraglutide soln pen-injector 18 mg/3 mL (Victoza)GLP-1 receptor agonist
    TRULICITY dulaglutide soln auto-injector 0.75 mg/0.5 mLGLP-1 receptor agonist
    Listed insulin productsmixed
    FIASP FLEXTOUCH 100 unit/mLinsulin aspart (with niacinamide) pen-injector
    FIASP PENFILL 100 unit/mLinsulin aspart cartridge (with niacinamide)
    NOVOLOG 100 unit/mLinsulin aspart solution
    HUMALOG 100 unit/mL (KwikPen, Junior KwikPen, Tempo Pen)insulin lispro presentations
    HUMULIN R U-500 500 unit/mLconcentrated insulin regular
    INSULIN ASPART FLEXPEN 100 unit/mLinsulin aspart pen-injector
    INSULIN ASPART PENFILL 100 unit/mLinsulin aspart cartridge
    NOVOLIN R 100 unit/mLinsulin regular (human)
    INSULIN LISPRO 100 unit/mLinsulin lispro solution
    LYUMJEV 100 unit/mL (and KwikPen 200/100 presentations)insulin lispro-aabc product and pen forms
    Insulin product listingsmixed
    insulin lispro-aabc soln pen-injector 200LYUMJEV KWIKPEN insulin lispro-aabc solution pen-injector (200 units/mL) — listed
    insulin lispro prot & lispro sus pen-inj 100 unitlml (75-25)HUMALOG MIX 75/25 KWIKPEN — insulin lispro protamine & lispro suspension pen-injector 100 units/mL (75/25)
    insulin nph (human) (isophane) inj 100 unitlmlHUMULIN N insulin NPH injectable 100 units/mL
    Additional insulin product listingsmixed
    NOVOLIN N FLEXPEN insulin nphNOVOLIN N FLEXPEN insulin NPH suspension pen-injector 100 units/mL
    NOVOLIN 70/30 insulin nph isophane & regular human inj 100 unitlml (70-30)NOVOLIN 70/30 premixed insulin 100 units/mL (70/30)
    Thyroid product listingsmixed
    liothyronine sodium tab 25 mcg; 50 mcgLiothyronine sodium (Cytomel) tablets 25 mcg and 50 mcg
    methimazole tab 5 mg; 10 mgMethimazole (Tapazole) tablets 5 mg and 10 mg
    NP THYROID 15/30/120 thyroid tabNP Thyroid compounded/desiccated thyroid tablets in multiple strengths (15 mg, 30 mg, 120 mg)
    Listed formulations (partial cartridge descriptions)mixed
    5.8 mgOMNITROPE somatropin solution cartridge 5 mg/1.5ml, 10
    10 mg/1.mlOMNITROPE somatropin solution cartridge 10 mg/1.ml (various references)
    Oral nitrate formulationsmixed
    10 mg; 20 mg; 30 mgisosorbide dinitrate tab strengths
    30 mg; 60 mg; 120 mgisosorbide mononitrate tab ER 24hr strengths
    Nitroglycerin productsmixed
    0.3 mg; 0.4 mg; 0.6 mgnitroglycerin sublingual tablet (Nitrostat) strengths
    0.4 mg/spray (400 mcg/spray)nitroglycerin topical solution/spray (Nitrolingual)
    0.1 mg/hr; 0.2 mg/hr; 0.4 mg/hrnitroglycerin transdermal patch 24hr strengths (Nitro-Dur)
    Cardiac agents / Beta blockersmixed
    500 mg; 1000 mgranolazine ER tablet 12hr 500 mg; 1000 mg
    25 mg; 50 mg; 100 mg; 400 mgatenolol and other beta blocker tablet strengths referenced
    Sapropterin (Kuvan)mixed
    100 mg; 500 mgsapropterin dihydrochloride powder packet 100 mg, 500 mg (Kuvan)
    100 mg tabletsapropterin dihydrochloride tablet (Kuvan)
    Other specialty injectables/oral powdersmixed
    3 gsodium phenylbutyrate oral powder 3 g/teaspoonful
    10000 unitPREGNYL chorionic gonadotropin for IM injection 10000 unit
    Listed drugs (sample)NDC | mixed
    sapropterin dihydrochloride tab 100 mg (Kuvan) — product name repeated
    Listed drugs (Buphenyl)mixed
    powder 3 g/teaspoonful (Buphenyl) — sodium phenylbutyrate oral powder
    Listed drugs (Digoxin)mixed
    digoxin oral soln 0.05 mg/mL (Digoxin)
    Cardiovascular agentsmixed
    various cardiovascular agents: carvedilol tabs, labetalol, metoprolol succinate ER (Toprol XL) — product names listed

    Prior Authorization, Step Therapy, Quantity Limits & Reconsideration

    Prior Authorization

    Prior authorization may be required for some drugs

    Some drugs listed in the formulary may require prior authorization; when PA is commonly required it is denoted by a dot in the Prior Authorization column adjacent to the drug entry. Providers must submit a prior authorization request for those drugs before coverage will be provided under the member's prescription drug plan.

    • PA requirement indicated by a dot in the Prior Authorization column when commonly applied
    • Provider must submit a PA request and obtain approval before the drug will be covered
    Prior Authorization

    PA indicated per drug in formulary columns

    Prior Authorization applicability is shown per drug by an entry in the Prior Authorization column; presence of that indicator means the plan's UM prior authorization requirement applies and the provider must follow the PA process described by the plan.

    • Check the Prior Authorization column for an indicator next to the drug
    • If indicated, follow the plan's PA submission process prior to dispensing
    Prior Authorization

    No prior authorization details in this listing segment

    This excerpt does not specify any specific prior authorization requirements for the products shown. The content in these chunks is a product listing and does not provide PA criteria or affected billing codes.

    • No drug-specific PA details are provided in this listing segment
    • Refer to the formulary columns or the member's plan materials for PA requirements
    Prior Authorization

    Formulary listing — PA not specified here

    The document fragment is a formulary product listing and does not state prior authorization requirements for the listed products. Providers should consult the formulary columns or the member's plan materials for UM indicators.

    • Formulary listing only; PA requirements not specified here
    • Use the Prior Authorization column in the full formulary to determine PA needs
    Prior Authorization

    PA not specified for vaccines/antineoplastics in this excerpt

    No explicit prior authorization requirements or affected billing codes are specified in this excerpt; the content is a formulary listing of vaccines and antineoplastic agents and their presentations only.

    • Vaccine and oncology product listings without PA mapping in this fragment
    • Check full formulary columns for PA indicators
    Prior Authorization

    PA not specified; codes not listed here

    This segment lists drug names, formulations, and strengths but does not specify which HCPCS/CPT/NDC codes require prior authorization. Providers should refer to the plan's UM resources for PA code mappings.

    • Drug entries shown without associated PA code requirements
    • Consult plan materials for PA coding and submission instructions
    Prior Authorization

    No PA rules in this formulary fragment

    Prior authorization requirements are not stated in this excerpt; the text is a formulary-style list of products and formulations and does not provide PA rules.

    • No PA rules presented in this fragment
    • Use the Prior Authorization column or plan documents for PA guidance
    Prior Authorization

    PA not specified in this section

    No explicit prior authorization requirements are stated in these chunks; the content is a medication listing and strengths without PA mapping.

    • Providers should not assume PA is or is not required based on this listing alone
    • Verify UM indicators in the formulary columns or member plan
    Prior Authorization

    PA not listed for these products

    No prior authorization statements are present in this portion; the text lists drug names and strengths only. Providers must check the Prior Authorization column or member-specific benefits for PA requirements.

    • Listing shows products but no PA criteria here
    • Confirm PA via formulary columns or Benefit Booklet
    Prior Authorization

    Product listing — PA not specified

    This section is a product/formulation listing and does not state specific prior authorization requirements. Providers should consult the full formulary columns and the member's Certificate of Coverage for PA applicability.

    • No PA criteria included in this listing
    • Use plan-specific materials to confirm PA needs
    Prior Authorization

    PA not specified in this fragment

    No explicit prior authorization requirements are stated in this document fragment; the content is a formulary/product listing without PA mapping. Verify PA requirements through the formulary columns or specific plan materials.

    • Listing does not identify PA-applicable codes
    • Confirm PA via the Prior Authorization column or Benefit Booklet
    Prior Authorization

    PA not specified for listed products

    This segment enumerates drug names and formulations but does not specify prior authorization requirements. Providers must check the formulary columns or contact plan administrators to determine PA obligations.

    • No PA mapping included here
    • Contact Prime Therapeutics/Capital Blue Cross or review full formulary columns for PA
    Prior Authorization

    PA not specified in this section

    No prior authorization requirements are stated in these chunks; the content is product/formulation names and classifications without PA instructions. Providers should consult plan-specific UM resources to confirm PA needs.

    • Listing only; no PA criteria present
    • Verify PA via formulary columns or member's plan
    Prior Authorization

    No PA requirement indicated in this fragment

    No prior authorization requirement is specified in this fragment. The listing repeats product entries but does not indicate applicable PA processes; check the formulary columns or plan materials for PA indicators.

    • Repeated product listings without PA indicators here
    • Refer to the Prior Authorization column or Benefit Booklet for requirements
    Prior Authorization

    PA not specified in this section

    No prior authorization requirements are specified in these pages; content is limited to drug names and formulations. Providers should verify PA via the formulary columns or the member's Certificate of Coverage.

    • Formulary entries only; no PA rules listed
    • Confirm PA with plan materials or specialty pharmacy when applicable
    Step Therapy

    Step therapy may apply to some drugs

    Some drugs may be subject to step therapy; when step therapy is commonly required it is indicated by a dot in the Step Therapy column next to the drug. Providers must follow the plan's step therapy requirements when the indicator is present.

    • Step therapy indicated by a dot in the Step Therapy column when commonly applied
    • Provider must document trial/failure of required preferred agents per plan before obtaining coverage
    Step Therapy

    Step therapy indicated per formulary entry

    Step Therapy is indicated per drug by an entry in the Step Therapy column; presence of that indicator means the plan may require a trial of preferred or cost‑effective agents before covering the requested drug.

    • Check the Step Therapy column for an indicator next to the drug
    • If present, document trials of required alternatives before requesting coverage
    Step Therapy

    No step therapy details in this listing

    No step therapy rules are stated in these chunks. The content is a product listing and does not provide step therapy criteria or required prior trials.

    • Listing segment only; no step therapy details provided
    • Consult formulary columns or plan materials for step therapy applicability
    Step Therapy

    Step therapy not specified in this segment

    This fragment does not include step therapy rules. Providers should rely on the Step Therapy column in the complete formulary or the member's plan documents to determine whether step therapy applies.

    • No step therapy criteria included here
    • Verify step requirements via the Step Therapy column or plan materials
    Step Therapy

    No step therapy rules in this fragment

    No step therapy rules are present in these chunks; content is product listings and presentation details. Check the Step Therapy column in the full formulary for any program indicators.

    • Vaccine/antineoplastic listings without step therapy mapping here
    • Confirm step therapy through formulary columns or plan contact
    Step Therapy

    Step therapy not stated here

    No step therapy rules are provided in these chunks. Providers should not assume step therapy requirements from this listing and must check the formulary columns or plan materials for step therapy indicators.

    • Product listing does not include step therapy criteria
    • Use plan-specific UM resources to confirm step therapy
    Step Therapy

    No step therapy requirements in this section

    No step therapy requirements are specified in these chunks. The document segments are drug listings without step therapy mapping; refer to the formulary columns or plan documentation for step therapy details.

    • No step therapy criteria shown in these listings
    • Confirm step therapy via the Step Therapy column in the full formulary
    Step Therapy

    Step therapy not indicated for these entries

    No step therapy rules are specified in this fragment. Providers should consult the Step Therapy column or the member's plan materials for any required prior trials before coverage.

    • Insulin and diabetes product listings here do not include step therapy details
    • Check formulary columns for step therapy indicators
    Step Therapy

    No step therapy described in this fragment

    No step therapy rules are described in these chunks. The product listings in this fragment lack step therapy mapping; verify step therapy applicability via the full formulary columns.

    • Thyroid and endocrine listings without step therapy info here
    • Confirm step therapy via plan materials when needed
    Step Therapy

    Step therapy not specified in this fragment

    No step therapy requirements are specified in this fragment. Providers must consult the formulary Step Therapy column or their prescription drug plan materials for any applicable requirements.

    • Specialty metabolic and other agents listed without step therapy mapping
    • Refer to plan-specific UM resources for step therapy
    Step Therapy

    No step therapy rules in this section

    No step therapy requirements are specified in these pages; content is product listings repeated across the formulary. Providers should check the Step Therapy column or member plan materials to determine if step therapy applies.

    • Repeated product listings without step therapy indicators here
    • Confirm step therapy via the formulary's Step Therapy column
    Note
    Note
    Note
    Note
    Documentation Required

    Request formulary tier reconsideration / appeals

    Providers may request a formulary tier reconsideration by completing a Formulary Status Reconsiderations form or by sending a letter describing the drug's significant advantages; the P&T Committee will review requests and communicate results, and patient‑specific requests must follow the dispute and appeal process.

    • Complete the Formulary Status Reconsiderations form or submit a detailed letter to the P&T Committee
    • P&T Committee will review and communicate outcomes; patient-specific reviews follow the dispute/appeal process
    Documentation Required

    Use formulary columns to determine UM and dispensing

    Prescribers and pharmacists should use the formulary columns (Prior Authorization; Step Therapy; Quantity Level Limits; Limited Distribution) to determine required utilization management actions and where the drug must be dispensed.

    • Check the Prior Authorization, Step Therapy, Quantity Level Limits, and Limited Distribution columns for UM and dispensing instructions
    • If an indicator is present, follow the corresponding UM or limited distribution requirements
    Note
    Note
    Documentation Required

    Reference product presentation for coding/documentation

    This segment contains product names, formulations, and presentation details (e.g., dose, volume, prefilled syringe) that providers should reference when coding and documenting vaccine or antineoplastic drug administration, but it does not provide explicit documentation requirements.

    • Use the listed product formulation and presentation details for accurate coding and documentation
    • No specific documentation forms or fields are specified in these chunks
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Denial Risk

    Formulary listing does not guarantee coverage — PA may cause denial

    Coverage of a drug is not guaranteed by its listing in the formulary; prior authorization may be required and lack of approval will result in denial of coverage.

    • A formulary listing alone does not ensure coverage or payment
    • If PA is required and not approved, the claim may be denied
    Denial Risk

    UM indicators may trigger claim denials if unmet

    If an indicator for Prior Authorization, Step Therapy, or Quantity Limits is present in the formulary columns, utilization management programs may apply and claims lacking required UM may be denied. Providers must follow UM requirements indicated in the formulary columns.

    • Presence of UM indicators in the formulary columns signals applicable UM programs
    • Claims submitted without required UM (e.g., PA approval) may be denied
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Step Therapy Rules & Indicators

    Step therapy overview
    Step therapy may require trying a proven, cost‑effective alternative prior to coverage of the requested drug; if commonly required it is indicated with a dot in the Step Therapy column next to the drug.
    Step therapy indicator
    Presence of an indicator in the Step Therapy column of the formulary denotes the plan may require trials of preferred agents before coverage of the listed drug.

    Quantity Limits & Dispensing Constraints

    Quantity Limits (unspecified list entries)
    Quantity limits indicatorCertain drugs have quantity level limits (QLL) which are noted with a dot in the Quantity Level Limits column next to the drug.
    Limit typesLimits may specify quantity per prescription, quantity within a time period, age-based limits, or gender-based limits.
    Exceeding limitsIf a prescribed quantity exceeds the QLL, the member may obtain the drug but is responsible for the full cost beyond the covered quantity.
    PurposeQLLs are applied to support safety of certain medications.

    Site of Care and Medical Benefit Notes

    Billing Rule

    Confirm site-of-care and medical benefit billing for certain injectables

    Some non-self-administered injectable drugs may be covered under the member's medical benefit and distributed through Accredo; providers should confirm site-of-care coverage (infusion center, hospital outpatient, or office) and billing pathways with the plan.

    • Non–self-administered injectables may be billed to medical benefit rather than pharmacy
    • Accredo may assist with distribution and billing for select medical injectables; contact 833.721.1626 or fax 888.302.1028 for service

    Terminology and Abbreviations

    Specialty drugs — definition
    DefinitionSpecialty drugs are medications used to treat complex conditions (e.g., hepatitis, multiple sclerosis, rheumatoid arthritis) that may be oral or injectable and can be self-administered or provider-administered.
    DistributionSpecialty drugs are distributed through the plan's specialty pharmacy (Accredo) and some are limited distribution, restricting dispensing to select pharmacies.
    Supply/handlingSpecialty medications may have program-specific dispensing and enrollment requirements; members may be required to use designated specialty pharmacy services (Accredo).
    Coverage eligibility
    FDA approval requirementCovered drugs are limited to FDA‑approved medications with an NDA, ANDA, or BLA on file, unless legal requirements or group‑specific benefits supersede.
    Noncovered examplesDrugs not approved by the FDA are not covered; coverage may be subject to contractual exclusions per the member's Certificate of Coverage.
    Exception processIf a provider believes a non‑formulary/new drug is medically necessary before P&T Committee evaluation, a nonformulary exception request may be submitted.
    Formulary labeling conventions
    Generic vs Brand formattingGeneric drugs are listed in lowercase boldface; brand name drugs are listed in CAPITAL LETTERS.
    Program tagsPreventive Health Care drugs are marked 'PH'; Generics Preferred 'GP'; Generics Nonpreferred 'GN'; Brands Preferred 'BP'; Brands Nonpreferred 'BN'; Specialty Preferred 'SP'; Specialty Nonpreferred 'SN'.
    Column guidanceEach drug entry includes multiple columns (e.g., Drug Name, Tier, Specialty) used to convey formulary status and UM markers.
    Abbreviation key (dosage forms & units)
    Common dosage form abbreviationscap = capsules; susp = suspension; soln = solution; tab = tablets; inj = injection; td = transdermal; er = extended release.
    Unit abbreviationsmg = milligram; mL = milliliter; gm = gram.
    Other form abbreviationsaer = aerosol; chew = chewable; cr = controlled release; ec = enteric coated; odt = orally disintegrating tablet.
    PH / PHI / SP / SN / GP / GN / BP / ER — abbreviation tags
    Tag meaningsAbbreviation tags adjacent to product names (e.g., PH, PHI, SP, SN, GP, GN, BP) denote internal classification or program flags used on the formulary.
    ExamplesPH = Preventive Health; GP = Generics Preferred; GN = Generics Nonpreferred; SP = Specialty Preferred; SN = Specialty Nonpreferred; BP = Brands Preferred.
    UsageThese tags are displayed next to drug entries to indicate formulary tiering and program status; exact internal code definitions are provided in the formulary key.
    testosterone td gel — listed formulations
    Testosterone TD gel examplesTestosterone transdermal gel entries include 12.5 mg/act (1%) and 20.25 mg/act (1.62%) with brand mentions such as Androgel.
    PresentationTD gel strengths and metered‑dose pump presentations are listed in the formulary.
    Formulary markingsTestosterone TD gel entries may carry formulary tags (e.g., GN, PH) consistent with other product listings.
    estradiol / estrogens — listed formulations
    Estradiol formulations listedEstradiol appears in multiple formulations including gel (Estrogel 0.06%), oral tablets (Estrace 0.5 mg, 1 mg, 2 mg), and transdermal patches (Vivelle‑Dot weekly/biweekly strengths).
    Injectable formEstradiol valerate IM in oil (Delestrogen) is also listed among formulations.
    Contraceptive/related entriesEstradiol products are listed alongside contraceptive rings and combined formulations (e.g., Nuvaring, combined oral contraceptives).
    FIASP FLEXTOUCH — product reference
    FIASP FLEXTOUCH definitionFIASP FLEXTOUCH is listed as insulin aspart (with niacinamide) rapid‑acting solution pen‑injector at 100 units/mL.
    Alternate presentationsFIASP is also listed in PENFILL cartridges (100 units/mL) and referenced alongside other insulin aspart products.
    Formulary taggingFIASP entries carry formulary indicators consistent with insulin product listings (e.g., BP in some entries).
    HUMALOG / insulin lispro — product definitions
    HUMALOG definitionHUMALOG is insulin lispro injection solution 100 units/mL available in multiple pen and cartridge presentations (e.g., KwikPen, Junior KwikPen, Tempo Pen).
    Mixtures and presentationsHUMALOG is also available in premix forms (HUMALOG MIX 75/25 KwikPen) and in standard 100 units/mL vials/cartridges.
    Formulary tagsHUMALOG entries are shown with formulary status tags (e.g., BP) in the product listing.
    HUMALOG MIX 75/25 KWIKPEN — product definition
    Product descriptionHUMALOG MIX 75/25 KWIKPEN is a premixed insulin containing insulin lispro protamine suspension and lispro solution in a 75/25 ratio provided as a 100 units/mL pen‑injector.
    PresentationAvailable as KwikPen premix presentation with standard pen dosing features.
    Formulary contextListed alongside other premixed and premade insulin products in the formulary insulin section.
    HUMULIN N — product definition
    HUMULIN N definitionHUMULIN N is insulin NPH (isophane) injectable at 100 units/mL for glycemic management.
    PresentationsListed in vials and pen formats consistent with other insulin NPH products.
    Formulary taggingHUMULIN N entries appear with formulary status indicators (e.g., BP) in the insulin product listing.
    Liothyronine sodium (Cytomel) — thyroid product reference
    Liothyronine (Cytomel)Liothyronine sodium (Cytomel) tablets listed in 25 mcg and 50 mcg strengths.
    Formulary tagEntries include formulary annotations (e.g., GN, SP) consistent with thyroid product listings.
    Related productsLiothyronine is listed alongside other thyroid agents and antithyroid medications in the endocrine section.
    sodium phenylbutyrate (Buphenyl) — oral powder
    Sodium phenylbutyrate (Buphenyl)Sodium phenylbutyrate is listed as an oral powder at 3 g per teaspoonful (Buphenyl).
    Repeated listingThe oral powder formulation is referenced multiple times in the formulary listing.
    Program tagEntries include specialty/product flags consistent with other specialty metabolic agents.
    digoxin oral solution 0.05 mg/mL — formulation reference
    Digoxin oral solution strengthDigoxin oral solution 0.05 mg/mL is listed repeatedly in the formulary product entries.
    Multiple referencesThe digoxin 0.05 mg/mL solution appears across several listing segments, indicating repeated formulary presence.
    Therapeutic groupingListed within cardiovascular/cardiotonics product group alongside other cardiac agents.
    digoxin oral solution 0.05 mg/mL — repeated listing
    Repeated entryDigoxin oral solution 0.05 mg/mL is reiterated multiple times in this section of the formulary.
    Formulary placementAppears under cardiovascular agents/cardiotonics where other cardiac medications are listed.
    Classification tagEntries carry formulary classification markers (e.g., GN) as applicable.
    Toprol XL (metoprolol tartrate/extended-release reference)
    Toprol XL referenceToprol XL (metoprolol succinate extended‑release) is referenced with tartrate equivalent strengths: 25 mg, 50 mg, 100 mg, 200 mg.
    ContextToprol XL appears in the cardiovascular product listings adjacent to digoxin and other beta‑blockers.
    Formulary notationStrengths are listed as tartrate equivalents in the formulary entries.

    Policy Background

    Specialty drugs are used to treat complex, chronic, or rare conditions such as hepatitis, multiple sclerosis, and rheumatoid arthritis and may be oral or injectable and self‑administered or provider‑administered. Specialty medications are typically distributed through the plan’s designated specialty pharmacy (Accredo) and may be subject to limited distribution, requiring dispensing from specified pharmacies. Coverage is determined by FDA approval status and the member’s Certificate of Coverage; utilization management tools such as prior authorization, step therapy, and quantity level limits may apply.